Determining functional B cell response in lung cancer

Not Applicable

Suspended

• Conditions: on-Small Cell Lung Cancer; Cancer

• Registration Number: ISRCTN49173282
• Lead Sponsor: niversity of Birmingham

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-02
• Last Update Posted: 26 October 2020
• Study Completion: 2022-10-20

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Patient is able to give informed consent and undertake the patient assessment as detailed in the protocol
2. Patient has resectable NSCLC and be scheduled for surgical resection of the NSCLC from the time of baseline blood withdrawal OR has advanced disease NSCLC that is eligible for chemo/immunotherapy
3. Patient is aged 65 or over OR patient is aged between 18 to 65 years AND have a long-term health condition such as COPD, diabetes, chronic kidney disease or liver disease, and therefore meeting standard of care requirements for PPSV23 vaccination

Exclusion Criteria

1. Previously vaccinated with the PPSV23 vaccine in the last 5 years
2. Oral steroids or other form of immunosuppression that will affect vaccine response
3. Suppressed immune system caused by a health condition such as HIV
4. Allergic to components of the study vaccines
5. Suffering from an acute infective illness (as determined by the clinician at visit 2)

Study & Design

• Study Type: Interventional
• Study Design: Not specified